Summary: In a 52-week randomised trial in type 2 diabetes, once-weekly semaglutide reduced weight, waist, and HbA1c and shifted LDL and HDL subfractions toward a less atherogenic profile, changes that were independent of weight or glucose change, whereas sitagliptin improved glucose modestly without altering lipids.
PICO Summary
| Element | Detail |
|---|---|
| Population | 34 obese adults with type 2 diabetes (plus 31 matched non-diabetic controls); Hungary. |
| Intervention | Once-weekly subcutaneous semaglutide for 52 weeks (n=18), with lipoprotein subfractions by Lipoprint electrophoresis. |
| Comparison | Once-daily oral sitagliptin (n=16). |
| Outcome | Semaglutide significantly reduced BMI, waist circumference, and HbA1c, lowered LDL and non-HDL cholesterol, and redistributed LDL and HDL subfractions toward a less atherogenic pattern. These subfraction changes were not explained by changes in BMI or HbA1c. Sitagliptin produced modest glycaemic improvement without substantial lipid change. |
Semaglutide vs sitagliptin on lipids in T2D
RCT · type 2 diabetes · 52 weeks
Over 52 weeks semaglutide cut HbA1c by 1.5% and weight by 8.1% and lowered LDL/non-HDL while raising HDL, with a less atherogenic subfraction shift independent of weight or glucose change. Sitagliptin improved glucose modestly with no meaningful lipid effect.
Expert Commentary
This is a mechanistically interesting small study, and its most intriguing claim is not simply that semaglutide improved the lipid panel, but that it shifted lipoprotein subfractions toward a less atherogenic profile in a way that statistically did not depend on weight loss or glycaemic improvement. If that holds, it points to a direct or pleiotropic effect on lipoprotein metabolism beyond the obvious downstream consequences of losing weight, which would be a satisfying partial explanation for the cardiovascular benefits of the class. I stay measured because the study is small, with only eighteen patients on semaglutide, the lipoprotein-subfraction method is informative but not a hard outcome, and a single-centre design limits generalisability. The comparison with sitagliptin is fair but unsurprising, since DPP-4 inhibitors are not expected to move lipids much. Can I use this with my patients? Supportively rather than decisively. It adds to my confidence that a GLP-1 agonist offers cardiometabolic benefit beyond glucose lowering, including on the lipid front, which is relevant when choosing therapy for a diabetic patient at vascular risk. I would still rely on outcome trials, not subfraction analyses, for the actual cardiovascular case.
References
Tóth LI, Harsányi A, Csiha S, et al. Semaglutide improves lipid subfraction profiles in type 2 diabetes: insights from a one-year follow-up study. Int J Mol Sci. 2025;26(13):5951. doi:10.3390/ijms26135951